Ideaya Biosciences Stock Performance
| IDYA Stock | USD 27.36 0.37 1.37% |
The company retains a Market Volatility (i.e., Beta) of 1.58, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ideaya Biosciences will likely underperform. At this point, Ideaya Biosciences has a negative expected return of -0.47%. Please make sure to check out Ideaya Biosciences' potential upside, and the relationship between the total risk alpha and daily balance of power , to decide if Ideaya Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ideaya Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.37 | Five Day Return 0.81 | Year To Date Return (22.32) | Ten Year Return 144.5 | All Time Return 144.5 |
1 | IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition ... | 10/04/2024 |
2 | This Cognex Analyst Is No Longer Bullish Here Are Top 5 Downgrades For Tuesday | 11/05/2024 |
3 | Wall Street Analysts Predict an 81.88 percent Upside in IDEAYA Biosciences Heres What You Should Know | 11/07/2024 |
4 | Biocytogen Announces IDEAYAs Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 11/11/2024 |
5 | IDEAYAB7H3PTK7ADC | 11/13/2024 |
6 | Significant Portfolio Adjustment by Biotechnology Value Fund L.P. in IDEAYA Biosciences Inc | 11/15/2024 |
7 | IDEAYA Biosciences Now Covered by Analysts at Stephens | 11/21/2024 |
8 | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 | 11/29/2024 |
| Begin Period Cash Flow | 68.7 M |
Ideaya |
Ideaya Biosciences Relative Risk vs. Return Landscape
If you would invest 3,811 in Ideaya Biosciences on September 2, 2024 and sell it today you would lose (1,075) from holding Ideaya Biosciences or give up 28.21% of portfolio value over 90 days. Ideaya Biosciences is currently does not generate positive expected returns and assumes 2.9063% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Ideaya, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ideaya Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ideaya Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ideaya Biosciences, and traders can use it to determine the average amount a Ideaya Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1632
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IDYA |
Estimated Market Risk
| 2.91 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ideaya Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ideaya Biosciences by adding Ideaya Biosciences to a well-diversified portfolio.
Ideaya Biosciences Fundamentals Growth
Ideaya Stock prices reflect investors' perceptions of the future prospects and financial health of Ideaya Biosciences, and Ideaya Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ideaya Stock performance.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (57.31) % | ||||
| Current Valuation | 1.46 B | ||||
| Shares Outstanding | 86.43 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 602.95 X | ||||
| Revenue | 23.39 M | ||||
| Gross Profit | (38.6 M) | ||||
| EBITDA | (130.42 M) | ||||
| Net Income | (112.96 M) | ||||
| Cash And Equivalents | 268.62 M | ||||
| Cash Per Share | 6.83 X | ||||
| Total Debt | 2.87 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.69 X | ||||
| Book Value Per Share | 13.67 X | ||||
| Cash Flow From Operations | (115.22 M) | ||||
| Earnings Per Share | (2.33) X | ||||
| Market Capitalization | 2.36 B | ||||
| Total Asset | 649.32 M | ||||
| Retained Earnings | (348.36 M) | ||||
| Working Capital | 505.53 M | ||||
| Current Asset | 93.24 M | ||||
| Current Liabilities | 6.51 M | ||||
About Ideaya Biosciences Performance
By analyzing Ideaya Biosciences' fundamental ratios, stakeholders can gain valuable insights into Ideaya Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ideaya Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ideaya Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.3 K | -1.4 K | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.18) | (0.17) |
Things to note about Ideaya Biosciences performance evaluation
Checking the ongoing alerts about Ideaya Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ideaya Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ideaya Biosciences generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 23.39 M. Net Loss for the year was (112.96 M) with loss before overhead, payroll, taxes, and interest of (38.6 M). | |
| Ideaya Biosciences currently holds about 268.62 M in cash with (115.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.83. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 |
- Analyzing Ideaya Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ideaya Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ideaya Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ideaya Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ideaya Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ideaya Biosciences' stock. These opinions can provide insight into Ideaya Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ideaya Stock analysis
When running Ideaya Biosciences' price analysis, check to measure Ideaya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ideaya Biosciences is operating at the current time. Most of Ideaya Biosciences' value examination focuses on studying past and present price action to predict the probability of Ideaya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ideaya Biosciences' price. Additionally, you may evaluate how the addition of Ideaya Biosciences to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |